Geographic Atrophy Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Alexion, Alkeus, Annexon, Boehringer Ingelheim, Eyevensys, Genentech, Ionis, IVERIC, Novartis

September 26 23:50 2023
Geographic Atrophy Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Alexion, Alkeus, Annexon, Boehringer Ingelheim, Eyevensys, Genentech, Ionis, IVERIC, Novartis
Delveinsight Business Research LLP
As per DelveInsight, the Geographic Atrophy Market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, a better understanding of pathophysiology, and the expected launch and readily uptake of emerging therapies along with premium price agents like gene therapies.

Some of the major pharma and biotech companies such as Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Gyroscope Therapeutics, and others are actively working in the Geographic Atrophy Market.

DelveInsight’s “Geographic Atrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Geographic Atrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Geographic Atrophy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Geographic Atrophy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Geographic Atrophy: An Overview

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.

Geographic Atrophy is a progressive, irreversible, and blinding disease that tends to affect both eyes. Nearly two-thirds of geographic atrophy cases are reported in people aged 80 years and above. Geographic Atrophy is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.

Geographic Atrophy is characterized by one or more distinct dark patches on the retina, with corresponding areas of reduced vision or ‘blind spots’. These dark patches represent the death of different cell types in the retina, including the light-sensitive photoreceptors. A visual acuity test is used to assess Geographic Atrophy. Unfortunately; visual acuity alone does not fully capture the functional impact of Geographic Atrophy such as loss of reading ability, highlighting the need for improved testing.

Geographic Atrophy Market Key Facts

  • In the 7MM, the total diagnosed cases of Geographic Atrophy were 2,822,853 cases in 2021.

  • Globally, more than 5 million people are affected by Geographic Atrophy. Also, as per the published study by the GER group, the global prevalence of Geographic Atrophy is 0.66% in all ages, but it occurs in 0.34% of 65–74 years old, 1.3% for 75–84, and 4.4% over 85 years old.

  • According to the research study of Friedman et al., 2004, the overall prevalence rate of geographic atrophy in the US population 40 years and older was 0.81 per 100 people.

  • As per Boyer et al. (2017), approximately 973,000 people in the United States and approx. five million globally have Geographic Atrophy in at least one eye.

  • As per the National Institute for Health and Care Excellence (NICE) 2019, the prevalence rate of Geographic Atrophy in the United Kingdom was found to be between 1.3%-6.7%.

  • According to Y. Sakurada (2016), the prevalence of Geographic Atrophy was 6.6% among elderly Japanese with AMD.

Geographic Atrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Geographic Atrophy pipeline therapies. It also thoroughly assesses the Geographic Atrophy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Geographic Atrophy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Geographic Atrophy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Geographic Atrophy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Geographic Atrophy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Geographic Atrophy Epidemiology, Segmented as –

  • Total Prevalent Cases of Geographic Atrophy in the 7MM [2019–2032]

  • Total Geographic Atrophy Cases by Visual Impairment in the 7MM [2019–2032]

  • Total Diagnosed Cases of Geographic Atrophy in the 7MM [2019–2032]

  • Total Diagnosed Cases of Geographic Atrophy by Age Distribution in the 7MM [2019–2032]

  • Treated cases of Geographic Atrophy in the 7MM [2019–2032]

Geographic Atrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Geographic Atrophy market or expected to be launched during the study period. The analysis covers the Geographic Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Geographic Atrophy drugs based on their sale and market share.

The report also covers the Geographic Atrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Geographic Atrophy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Geographic Atrophy Market Will Evolve and Grow by 2032 @

Geographic Atrophy Therapeutics Analysis

Currently, there are no approved treatments present for Geographic Atrophy. The Age-Related Eye Disease Study (AREDS) study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene and zinc could significantly reduce the risk of progressing to advanced AMD and sometimes low visual aids and counseling are also helpful. Several therapies which reached in advanced stage of development have already failed, however, currently, several therapies are in the pipeline to prevent the progression of Geographic Atrophy.

Several major pharma and biotech companies are developing therapies for Geographic Atrophy. Currently, IVERIC bio is leading the therapeutics market with its Geographic Atrophy drug candidates in the most advanced stage of clinical development.

Geographic Atrophy Companies Actively Working in the Therapeutics Market Include

Alexion, Alkeus Pharmaceuticals, Annexon Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma Inc, Boehringer Ingelheim, Catalyst Biosciences, Cell Cure Neurosciences LTD, Eyevensys, Gemini Therapeutics, Genentech, Gyroscope Therapeutics Limited, Hemera Biosciences, Ionis Pharmaceuticals, IVERIC bio, Iveric Bio (formerly Ophthotech Corporation), Nanoscope Therapeutics, Inc., NGM Biopharmaceuticals, Novartis, ONL Therapeutics, Regenerative Patch Technologies, LLC, Stealth BioTherapeutics Inc., and others. 

Emerging and Marketed Geographic Atrophy Therapies Covered in the Report Include:

Apellis Pharmaceuticals (Pegcetacoplan), Iveric bio (Zimura), Genentech/ Roche (RO7171009; RG6147), Ionis Pharmaceuticals/ Roche (IONIS-FB-LRx), NGMBiopharmaceuticals (NGM621), Stealth BioTherapeutics (Elamipretide), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences/ Lineage Cell Therapeutics/ Roche (OpRegen), Novartis (PPY988/GT005), Regenerative Patch Technologies (CPCB-RPE1), Luxa Biotechnology (RPESC-RPE-4W) and others are involved in developing treatments for GA.

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Geographic Atrophy Competitive Intelligence Analysis

4. Geographic Atrophy Market Overview at a Glance

5. Geographic Atrophy Disease Background and Overview

6. Geographic Atrophy Patient Journey

7. Geographic Atrophy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Geographic Atrophy Unmet Needs

10. Key Endpoints of Geographic Atrophy Treatment

11. Geographic Atrophy Marketed Therapies

12. Geographic Atrophy Emerging Drugs and Latest Therapeutic Advances

13. Geographic Atrophy Seven Major Market Analysis

14. Attribute Analysis

15. Geographic Atrophy Market Outlook (In US, EU5, and Japan)

16. Geographic Atrophy Companies Active in the Market

17. Geographic Atrophy Access and Reimbursement Overview

18. KOL Views on the Geographic Atrophy Market

19. Geographic Atrophy Market Drivers

20. Geographic Atrophy Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Psychosis Market

“Psychosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Psychosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Psychosis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States